MapLight Graham Net Net from 2010 to 2026
| MPLT Stock | 15.70 1.10 6.55% |
Graham Net Net | First Reported 2010-12-31 | Previous Quarter 1.89 | Current Value 1 | Quarterly Volatility 0.64257923 |
Check MapLight Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MapLight Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 7.21. MapLight financial statements analysis is a perfect complement when working with MapLight Therapeutics Valuation or Volatility modules.
MapLight | Graham Net Net | Build AI portfolio with MapLight Stock |
The evolution of Graham Net Net for MapLight Therapeutics Common provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how MapLight Therapeutics compares to historical norms and industry peers.
Latest MapLight Therapeutics' Graham Net Net Growth Pattern
Below is the plot of the Graham Net Net of MapLight Therapeutics Common over the last few years. It is MapLight Therapeutics' Graham Net Net historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in MapLight Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Graham Net Net | 10 Years Trend |
|
Graham Net Net |
| Timeline |
MapLight Graham Net Net Regression Statistics
| Arithmetic Mean | 0.55 | |
| Geometric Mean | 0.35 | |
| Coefficient Of Variation | 117.44 | |
| Mean Deviation | 0.50 | |
| Median | 0.22 | |
| Standard Deviation | 0.64 | |
| Sample Variance | 0.41 | |
| Range | 1.881 | |
| R-Value | 0.68 | |
| Mean Square Error | 0.24 | |
| R-Squared | 0.46 | |
| Significance | 0 | |
| Slope | 0.09 | |
| Total Sum of Squares | 6.61 |
MapLight Graham Net Net History
About MapLight Therapeutics Financial Statements
MapLight Therapeutics shareholders use historical fundamental indicators, such as Graham Net Net, to determine how well the company is positioned to perform in the future. Although MapLight Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in MapLight Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on MapLight Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Graham Net Net | 1.89 | 1.00 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for MapLight Stock Analysis
When running MapLight Therapeutics' price analysis, check to measure MapLight Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MapLight Therapeutics is operating at the current time. Most of MapLight Therapeutics' value examination focuses on studying past and present price action to predict the probability of MapLight Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MapLight Therapeutics' price. Additionally, you may evaluate how the addition of MapLight Therapeutics to your portfolios can decrease your overall portfolio volatility.